Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans

BACKGROUND: Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking. Recent ICI clinical pharmacology data demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Alyssa Marie M., Vu, Trang T., Liva, Sophia G., Chen, Min, Xie, Zhiliang, Thomas, Justin, Remaily, Bryan, Guo, Yizhen, Subrayan, Uma L., Costa, Travis, Helms, Timothy H., Irby, Donald J., Kim, Kyeongmin, Owen, Dwight H., Kulp, Samuel K., Mace, Thomas A., Phelps, Mitch A., Coss, Christopher C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420755/
https://www.ncbi.nlm.nih.gov/pubmed/34514376
http://dx.doi.org/10.1002/rco2.32

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420755/
https://www.ncbi.nlm.nih.gov/pubmed/34514376
http://dx.doi.org/10.1002/rco2.32

Ejemplares similares